Get started Log in

IMMX — Immix Biopharma Share News

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapNeutral

Brief: Immix Biopharma Announces Complete Response In Al Amyloidosis Clinical Trial
03/10/2023 14:29
Brief: Immix Biopharma Announces Complete Response In 9Th Relapsed/Refractory Al Amyloidosis Patient In Nxc-201 Clinical Trial At Ims 20Th Annual Meeting
03/10/2023 14:23
Brief: Immix Biopharma Inc Files For Shelf Of Up To 5.2 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
25/09/2023 21:19
Immix Biopharma up on FDA's 'orphan drug' tag for blood disorder therapy
21/09/2023 16:55
U.S. STOCKS ON THE MOVE-Netflix, AMC Entertainment, Nike
23/08/2023 18:59
Immix Biopharma gains on FDA's 'orphan drug' tag for blood cancer therapy
23/08/2023 15:43
Brief: U.S. Food And Drug Administration Approves Orphan Drug Designation For Immix Biopharma Nxc-201 As A Treatment For Multiple Myeloma
23/08/2023 13:38
Brief: Immix Biopharma Inc- Co Entered Into Securities Purchase Agreement With Certain Accredited Investor
22/08/2023 21:22
Brief: Immix Biopharma Announces Heather Landau Joins Nexcella Scientific Advisory Board
18/08/2023 15:17
Brief: Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout In Ongoing Phase 1B/2A IMX-110 Imminent-01 Clinical Trial
17/07/2023 16:03
Brief: Immix Biopharma Subsidiary Nexcella Completes Pre-Ind Meeting With FDA On Nxc-201 Us Clinical Trial
26/06/2023 19:28
Brief: Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, Former Chief Financial Officer Of Biomarin, To Board Of Directors
20/06/2023 16:17
Brief: Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program
14/06/2023 12:30
Brief: Immix Biopharma Unit Announces Start Of Nxc-201 Engineering Batches At U.S. Car-T Manufacturing Site
26/05/2023 14:54
Brief: Immix Biopharma Says Late-Breaking NXC-201 Data Abstract Accepted For Presentation At ASGCT
04/05/2023 18:49
Brief: Immix Biopharma Announces Positive Interim Data In Early-To-Mid-Stage Cancer Drug Trial
03/05/2023 15:04
Immix Biopharma rises as unit announces positive results for cell therapy
27/04/2023 16:32
Brief: Nexcella Announces Positive 58-Patient Nxc-201 Clinical Data 100% Overall Response Rate In Light Chain (Al) Amyloidosis
26/04/2023 22:56
Brief: Nexcella Announces 2023 Haematologica Editorial Highlighting Nxc-201 Efficacy In The Context Of U.S. FDA Approved Bcma Car T Cells
31/03/2023 13:08
Brief: Nexcella, An Immix Biopharma Subsidiary, Announces New Positive Nxc-201 Clinical Data Demonstrating 100% Complete Responses In Al Amyloidosis Patients + Additional Positive Multiple Myeloma Safety Data Demonstrating Nxc-201 Outpatient Car-T Treatment Potential
23/03/2023 13:13